Table 1.
Characteristics of patients with samples tested in this study.
| Variable | Throat swab (n = 147) | Gut swab (n = 74) | Plasma (n = 46) | P | |
|---|---|---|---|---|---|
| Sex, n (%) | |||||
| Female | 52 (35.4) | 28 (37.8) | 15 (32.6) | 0.842 | |
| Male | 95 (64.6) | 46 (62.2) | 31 (67.4) | ||
| Age (y) | |||||
| Median (IQR) | 60 (52, 71) | 60 (51, 71) | 63 (53, 68) | 0.869 | |
| 20–40 | 10 (6.8) | 8 (10.8) | 4 (8.7) | ||
| 41–60 | 64 (43.5) | 30 (40.5) | 18 (39.1) | ||
| < 60 | 73 (49.7) | 36 (48.6) | 24 (52.2) | ||
| Comorbidity, n (%) | |||||
| Hypertension | 55 (37.4) | 17 (23) | 18 (39.1) | 0.42 | |
| Diabetes | 21 (14.3) | 9 (12.2) | 7 (15.2) | ||
| CVD | 17 (11.6) | 10 (13.5) | 5 (10.9) | ||
| Heart disease | 19 (12.9) | 6 (8.1) | 6 (13) | ||
| None | 53 (36.1) | 30 (40.5) | 9 (19.6) | ||
| Days after treatment, n (%) | |||||
| 1 | 83 (56.5) | 29 (39.2) | 35 (76.1) | 0.0002a | |
| 5 | 30 (20.4) | 20 (27.0) | 10 (21.7) | ||
| 10 | 23 (15.6) | 12 (16.2) | 1 (2.2) | ||
| 14 | 11 (7.5) | 13 (17.6) | 0 (0) | ||
| Outcome | |||||
| Death | 42 (28.6) | 23 (31.1) | 22 (47.8) | 0.049 | |
| Recovery | 105 (71.4) | 51 (68.9) | 24 (52.2) | ||
| Treatment | |||||
| Lopinavir-Ritonavir | 77 (52.4) | 35 (47.3) | 21 (45.7) | 0.639 | |
| Standard Care | 70 (47.6) | 39 (52.7) | 25 (54.3) | ||
IQR, interquartile range; CVD, Cerebrovascular diseases.
a
Fisher exact test. Chi-square test was used for the remaining variables comparison if not indicated.